Buprenorphine naloxone film versus tablets for opioid use disorder
CADTH
Record ID 32018005335
English
Authors' objectives:
What is the comparative clinical effectiveness of sublingual buprenorphine/naloxone film versus tablets for people with opioid use disorder? What is the comparative cost-effectiveness of sublingual buprenorphine/naloxone film versus tablets for people with opioid use disorder? What are the evidence-based recommendations for sublingual buprenorphine/naloxone film for people with opioid use disorder?
Authors' results and conclusions:
Medication for opioid use disorder is essential for reducing cravings, withdrawal symptoms, and facilitating recovery, with buprenorphine being preferred over methadone by health care providers and people with opioid use disorder due to its lower overdose risk and perceived lower side effect profile.
In Canada, buprenorphine is available in various formulations, including buprenorphine-naloxone (BUP-NAL), commonly chosen for its safety benefits and convenience.
Sublingual buprenorphine-naloxone films offer faster dissolution and potentially other benefits compared to sublingual tablets, evaluating their comparative clinical and cost-effectiveness is important as they become more widely available.
Details
Project Status:
Completed
URL for project:
https://www.cadth.ca/buprenorphine-naloxone-film-versus-tablets-opioid-use-disorder
Year Published:
2023
URL for published report:
https://www.cadth.ca/buprenorphine-naloxone-film-versus-tablets-opioid-use-disorder
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
Country:
Canada
MeSH Terms
- Opioid-Related Disorders
- Substance-Related Disorders
- Buprenorphine
- Buprenorphine, Naloxone Drug Combination
- Opiate Substitution Treatment
- Administration, Sublingual
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.